HLA B Leader in Patients With Psoriatic Arthritis
- Sponsor
- Centre Hospitalier Universitaire, Amiens
- Study ID
- NCT07718815
- Status
- Recruiting
Conditions
- HLA B27
- HLA b Leader
- Psoriatic Arthritis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- blood test — BIOLOGICALAddition of an extra tube for blood tests (a single tube for genetic research), enabling phenotyping of the HLA B27 and HLA B leader genes.
Study Details
Psoriatic arthritis (PsA), a chronic immune-mediated heterogeneous inflammatory disease characterized by musculoskeletal inflammation (arthritis, enthesitis, spondylitis and dactylitis), usually occurs in patients with psoriasis. The spondyloarthritides (SPs) (of which psoriasis is one) are a group of inflammatory diseases that share an association with the HLA-B27 MHC class I molecule. Given this association, these diseases are classically regarded as disorders of adaptive immunity. In bone marrow donation, HLA-B exon 1 dimorphism (HLAB leader) is associated with risk of graft- versus-host disease, relapse and overall survival after unrelated hematopoietic cell transplantation (UHCT), haploidentical UHCT and cord transplantation. In the literature, there are no studies suggesting the involvement of the HLA B leader gene in MS and RPs. The main aim of this study is to compare the presence of the HLA B leader gene between a group of patients with psoriatic arthritis and a healthy group without inflammatory disease.
Key Dates
- First listed
- Jul 22, 2026
- Start date
- May 6, 2025
- Status verified
- Jul 2026
- Primary completion
- Sep 30, 2026
- Completion
- Sep 30, 2026
Study Design
- Enrollment
- 658 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- BASIC_SCIENCE
Arms
- Experimental: psoriatic rheumatism patientpatients with psoriatic arthritis
- Active Comparator: healthy grouppatients without inflammatory disease
Primary Outcome Measure
prevalence of HLA B leader in both groups [ Time Frame: 1 year ]
Central Contacts
- Vincent Goeb, Pr33+3.22.08.83.71
Find similar trials
Related Studies
- Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy ProjectRecruiting · University of California, San Diego · La Jolla, California
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Sacramento, California
- Rheumatology Patient Registry and BiorepositoryRecruiting · Yale University · New Haven, Connecticut
- Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint InhibitorsRecruiting · M.D. Anderson Cancer Center · Houston, Texas